Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (NCT07005752) titled 'A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones)' on May 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Myungmoon Pharma. Co. Ltd.
Condition:
Cholesterol Cholelithiasis
Intervention:
Drug: CnU cap. 250mg & Ursa placebo tab. 200mg
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: June 2025
Target Sample Size: 484
To know mo...